Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder (AC)

Endo Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Frozen Shoulder; Adhesive Capsulitis

Treatments: Other: Placebo; Biological: Collagenase Clostridium Histolyticum

Study type: Interventional

Funder types: Industry

Identifiers

NCT02006719

AUX-CC-871

Details and patient eligibility

About

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.

Full description

Study is a Phase 2b, double-blind, placebo-controlled study of the safety and efficacy of AA4500 for the treatment of adhesive capsulitis of the shoulder. To be eligible for treatment, a subject must have unilateral idiopathic adhesive capsulitis of the shoulder with restricted range of motion in the affected shoulder for at least 3 months but not more than 12 months. Subjects will be screened for study eligibility within 28 days before injection of study drug.

Approximately 300 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, subjects will be randomized 3:1 to receive 0.58 mg of AA4500 or placebo. Subjects will receive up to 3 injections of study drug. Each injection will be separated by a minimum of 21 days. Subjects will also be instructed in home shoulder exercises after the first injection.

Enrollment: 322 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months but not more than 12 months (Frozen Stage)

• Normal range of motion in the contralateral shoulder

• Restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:

  • Forward flexion
  • Abduction
  • External rotation with the elbow up to 90 degrees abduction
  • Internal rotation with the elbow up to 90 degrees abduction

Exclusion criteria

• Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:

  • physical therapy or acupuncture within 2 weeks before the first injection of study drug
  • intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve blocks; corticosteroids, electroanalgesic and/or thermoanalgesic modalities within 1 month before the screening visit
  • intra-articular or intrabursal injection(s) of sodium hyaluronate and/or glenohumeral distension arthrography within 3 months before the screening visit
  • surgical intervention (including shoulder manipulation under anesthesia) at any time

• Has any of the following conditions, as determined by investigator to be potentially confounding to the evaluation of safety and efficacy:

  • Adhesive capsulitis as a result of traumatic injury (ie, direct injury to the shoulder such as fracture of the humerus or clavicle immediately preceding the onset of this episode of adhesive capsulitis). Traumatic events in the past that are not temporally related to the onset of this episode of adhesive capsulitis would not necessarily exclude a subject from participating in the study.
  • Active subacromial impingement in the affected shoulder
  • Calcified tendonitis in the affected shoulder
  • Glenohumeral joint arthritis in the affected shoulder
  • Arthrosis of the affected shoulder
  • Chondrolysis of the affected shoulder
  • Subscapularis tendon rupture of the affected shoulder
  • Other rotator cuff injuries of the affected shoulder
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • Uncontrolled thyroid disease
  • History of thrombosis or post-thrombosis syndrome
  • Physical impairment that would preclude performing the protocol defined exercises
  • Active infection in area to be treated
  • Clinically significant neurological disease
  • Bleeding disorder
  • Chronic use of anticoagulation medications and the subject cannot be cleared medically to stop taking medication for 7 days prior to each injection. Less than or equal to 150 mg aspirin is allowed during the study.
  • Known active hepatitis A, B, or C
  • Other significant medical condition (eg, morbid obesity, cervical disc disease), which in the investigator's opinion would make the subject unsuitable for enrollment in the study

• Has received oral or intravenous steroids for any reason within 3 weeks before the screening visit

• Has received an investigational drug or treatment within 30 days before the first dose of study drug.

• Has a known allergy to collagenase or any other excipient of AA4500 or any other procedural medication.

• Has, at any time, received collagenase for the treatment of adhesive capsulitis.

• Is unable to undergo an x-ray or MRI (contraindication) evaluation of the affected shoulder.

• Is planning to be treated with commercial XIAFLEX at any time during the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

322 participants in 2 patient groups, including a placebo group

Collagenase Clostridium Histolyticum

Experimental group

Description:

Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.

Treatment:

Biological: Collagenase Clostridium Histolyticum

Placebo

Placebo Comparator group

Description:

Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.

Treatment:

Other: Placebo